bendamustine indications/contra

Stem definitionDrug idCAS RN
antineoplastic, alkylating agents, (beta-chloroethyl)amine derivatives 302 16506-27-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bendamustine
  • bendamustine hydrochloride
  • treanda
  • bendamustine HCl
A nitrogen mustard compound that functions as an ALKYLATING ANTINEOPLASTIC AGENT and is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA and NON-HODGKIN'S LYMPHOMA.
  • Molecular weight: 358.26
  • Formula: C16H21Cl2N3O2
  • CLOGP: 3.24
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 58.36
  • ALOGS: -3.76
  • ROTB: 9

Drug dosage:

None

Approvals:

DateAgencyCompanyOrphan
March 20, 2008 FDA CEPHALON

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 1634.48 45.00 474 6482 18501 3360402
Pyrexia 1366.90 45.00 602 6354 80513 3298390
Neutropenia 1121.89 45.00 409 6547 32977 3345926
Pancytopenia 799.12 45.00 275 6681 18545 3360358
Thrombocytopenia 765.21 45.00 315 6641 34953 3343950
Rash 695.95 45.00 365 6591 70456 3308447
Pneumonia 676.28 45.00 357 6599 69786 3309117
Anaemia 555.30 45.00 288 6668 54045 3324858
Lymphocyte count decreased 553.92 45.00 147 6809 4012 3374891
Neutrophil count decreased 521.53 45.00 172 6784 10101 3368802
Tumour lysis syndrome 507.68 45.00 122 6834 2197 3376706
Sepsis 462.68 45.00 216 6740 32157 3346746
Cytomegalovirus infection 369.50 45.00 109 6847 4398 3374505
White blood cell count decreased 348.40 45.00 164 6792 24783 3354120
Infection 339.44 45.00 162 6794 25240 3353663
Platelet count decreased 321.44 45.00 160 6796 27308 3351595
Extravasation 316.88 45.00 77 6879 1451 3377452
Progressive multifocal leukoencephalopathy 302.73 45.00 86 6870 3026 3375877
Infusion related reaction 289.20 45.00 115 6841 11506 3367397
Chills 283.59 45.00 137 6819 21885 3357018
Lymphopenia 278.63 45.00 84 6872 3649 3375254
Leukopenia 258.15 45.00 116 6840 15707 3363196
Prescribed underdose 256.50 45.00 66 6890 1582 3377321
Myelodysplastic syndrome 252.25 45.00 86 6870 5561 3373342
Nausea 249.32 45.00 248 6708 129397 3249506
Atrial fibrillation 240.76 45.00 126 6830 23815 3355088
Diarrhoea 235.16 45.00 218 6738 104130 3274773
Off label use 232.83 45.00 165 6791 53812 3325091
Autoimmune haemolytic anaemia 224.41 45.00 56 6900 1181 3377722
Bone marrow failure 214.57 45.00 85 6871 8402 3370501

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC L01AA09 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
ALKYLATING AGENTS
Nitrogen mustard analogues
MeSH PA D000477 Alkylating Agents
MeSH PA D000970 Antineoplastic Agents
MeSH PA D018906 Antineoplastic Agents, Alkylating
MeSH PA D009676 Noxae
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Chronic lymphoid leukemia, disease indication 92814006 DOID:1040
Follicular non-Hodgkin's lymphoma indication 308121000
Indolent B-Cell Lymphoma indication
Fluid volume disorder contraindication 1860003
Hyperkalemia contraindication 14140009
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Acute infectious disease contraindication 63171007
Kidney disease contraindication 90708001 DOID:2527
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Smokes tobacco daily contraindication 449868002
Chemotherapy-Induced Hyperuricemia contraindication
Mantle cell lymphoma off-label use 443487006

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.61 acidic
pKa2 6.18 Basic
pKa3 2.83 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
100MG/VIAL TREANDA CEPHALON N022249 March 20, 2008 RX POWDER IV (INFUSION) 8791270 Jan. 12, 2026 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
180MG/2ML (90MG/ML) TREANDA CEPHALON N022249 Sept. 13, 2013 RX SOLUTION IV (INFUSION) 8791270 Jan. 12, 2026 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
25MG/VIAL TREANDA CEPHALON N022249 May 1, 2009 RX POWDER IV (INFUSION) 8791270 Jan. 12, 2026 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
45MG/0.5ML (90MG/ML) TREANDA CEPHALON N022249 Sept. 13, 2013 RX SOLUTION IV (INFUSION) 8791270 Jan. 12, 2026 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 8791270 Jan. 12, 2026 FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR NON-HODGKIN'S LYMPHOMA
100MG/VIAL TREANDA CEPHALON N022249 March 20, 2008 RX POWDER IV (INFUSION) 8445524 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
100MG/VIAL TREANDA CEPHALON N022249 March 20, 2008 RX POWDER IV (INFUSION) 8669279 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
100MG/VIAL TREANDA CEPHALON N022249 March 20, 2008 RX POWDER IV (INFUSION) 8883836 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
100MG/VIAL TREANDA CEPHALON N022249 March 20, 2008 RX POWDER IV (INFUSION) 9533955 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
100MG/VIAL TREANDA CEPHALON N022249 March 20, 2008 RX POWDER IV (INFUSION) 9533955 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
25MG/VIAL TREANDA CEPHALON N022249 May 1, 2009 RX POWDER IV (INFUSION) 8445524 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
25MG/VIAL TREANDA CEPHALON N022249 May 1, 2009 RX POWDER IV (INFUSION) 8669279 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
25MG/VIAL TREANDA CEPHALON N022249 May 1, 2009 RX POWDER IV (INFUSION) 8883836 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
25MG/VIAL TREANDA CEPHALON N022249 May 1, 2009 RX POWDER IV (INFUSION) 9533955 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
25MG/VIAL TREANDA CEPHALON N022249 May 1, 2009 RX POWDER IV (INFUSION) 9533955 March 26, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
180MG/2ML (90MG/ML) TREANDA CEPHALON N022249 Sept. 13, 2013 RX SOLUTION IV (INFUSION) 8344006 Sept. 23, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
45MG/0.5ML (90MG/ML) TREANDA CEPHALON N022249 Sept. 13, 2013 RX SOLUTION IV (INFUSION) 8344006 Sept. 23, 2029 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9572796 Jan. 28, 2031 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9572796 Jan. 28, 2031 FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9572797 Jan. 28, 2031 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9572797 Jan. 28, 2031 FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 8609707 Aug. 11, 2031 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9000021 March 15, 2033 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9034908 March 15, 2033 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9144568 March 15, 2033 FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND/OR NON-HODGKINS LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9572887 March 15, 2033 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9572887 March 15, 2033 FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9579384 March 15, 2033 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9579384 March 15, 2033 FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9597397 March 15, 2033 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9597397 March 15, 2033 FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9597398 March 15, 2033 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9597399 March 15, 2033 FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
100MG/4ML (25MG/ML) BENDEKA EAGLE PHARMS N208194 Dec. 7, 2015 RX SOLUTION IV (INFUSION) 9597399 March 15, 2033 FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Histone deacetylase 3 Enzyme IC50 7.60 CHEMBL
Histone deacetylase 1 Enzyme IC50 7.77 CHEMBL
Histone deacetylase 2 Enzyme IC50 8.05 CHEMBL
Histone deacetylase 10 Enzyme IC50 7.14 CHEMBL
Histone deacetylase 8 Enzyme IC50 6.97 CHEMBL
Histone deacetylase 6 Enzyme IC50 8.22 CHEMBL
DNA DNA OTHER DRUG LABEL DRUG LABEL

External reference:

scroll-->
IDSource
4027339 VUID
N0000179513 NUI
C0525079 UMLSCUI
7478 IUPHAR_LIGAND_ID
D07085 KEGG_DRUG
427812009 SNOMEDCT_US
428012008 SNOMEDCT_US
134547 RXNORM
d07121 MMSL
4027339 VANDF
N0000176143 NDFRT
006925 NDDF
9266D9P3PQ UNII
5228 INN_ID
3543-75-7 SECONDARY_CAS_RN
65628 PUBCHEM_CID
CHEMBL487253 ChEMBL_ID
CHEMBL1201734 ChEMBL_ID
DB06769 DRUGBANK_ID
D000069461 MESH_DESCRIPTOR_UI
CHEBI:135515 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
BENDEKA HUMAN PRESCRIPTION DRUG LABEL 1 63459-348 INJECTION, SOLUTION 25 mg INTRAVENOUS NDA 18 sections
TREANDA HUMAN PRESCRIPTION DRUG LABEL 1 63459-390 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 25 mg INTRAVENOUS NDA 17 sections
TREANDA HUMAN PRESCRIPTION DRUG LABEL 1 63459-391 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS NDA 17 sections
TREANDA HUMAN PRESCRIPTION DRUG LABEL 1 63459-395 INJECTION, SOLUTION, CONCENTRATE 45 mg INTRAVENOUS NDA 17 sections
TREANDA HUMAN PRESCRIPTION DRUG LABEL 1 63459-396 INJECTION, SOLUTION, CONCENTRATE 180 mg INTRAVENOUS NDA 17 sections